6-chloro-N-(1-(2-chloroacetyl)pyrrolidin-3-yl)-7-iodo-4-oxo-1,4-dihydroquinoline-2-carboxamide

ID: ALA5278066

Max Phase: Preclinical

Molecular Formula: C16H14Cl2IN3O3

Molecular Weight: 494.12

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(NC1CCN(C(=O)CCl)C1)c1cc(=O)c2cc(Cl)c(I)cc2[nH]1

Standard InChI:  InChI=1S/C16H14Cl2IN3O3/c17-6-15(24)22-2-1-8(7-22)20-16(25)13-5-14(23)9-3-10(18)11(19)4-12(9)21-13/h3-5,8H,1-2,6-7H2,(H,20,25)(H,21,23)

Standard InChI Key:  UWXHPPZSMIHWRD-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
   -3.8266    0.4956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1121    0.9079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4002    0.4960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4002   -0.3291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1102   -0.7409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8266   -0.3328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6855   -0.7416    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9709   -0.3291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2562   -0.7416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4583   -0.3291    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1729   -0.7416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6855    0.9086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9709    0.4960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6855    1.7338    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2562   -1.5669    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.9264   -0.4062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4783   -1.0191    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0659   -1.7334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2591   -1.5619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5413    0.9082    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -4.5413   -0.7453    0.0000 I   0  0  0  0  0  0  0  0  0  0  0  0
    3.3035   -1.0191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7161   -0.3045    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.7161   -1.7338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5413   -1.7338    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  4  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 11 10  1  0
  3 12  1  0
 12 13  1  0
  8 13  2  0
 12 14  2  0
  9 15  2  0
 16 11  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 11  1  0
  1 20  1  0
  6 21  1  0
 17 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
M  END

Alternative Forms

  1. Parent:

    ALA5278066

    ---

Associated Targets(Human)

NCI-H358 (882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H23 (49055 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H2228 (1030 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 494.12Molecular Weight (Monoisotopic): 492.9457AlogP: 2.36#Rotatable Bonds: 3
Polar Surface Area: 82.27Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 11.82CX Basic pKa: CX LogP: 2.26CX LogD: 2.26
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.51Np Likeness Score: -1.39

References

1. Cheng R, Lv X, Bu H, Xu Q, Wu J, Xie K, Tang J, Wang L, Zhuang J, Zhang Y, Zhang Y, Yan C, Lai Y..  (2022)  Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRASG12C inhibitors with potent antitumor activity against KRAS-mutant non-small cell lung cancer.,  244  [PMID:36228411] [10.1016/j.ejmech.2022.114808]

Source